$JAGX
Jaguar Health, Inc.

2021 Q3 Form 10-Q Financial Statement

#000155837021016117 Filed on November 17, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q4
Revenue $630.0K $385.0K $2.580M
YoY Change -77.26% -87.85% 70.86%
Cost Of Revenue $617.0K $664.0K $790.0K
YoY Change -21.3% -35.6% 6.76%
Gross Profit $13.00K -$279.0K $1.790M
YoY Change -99.35% -113.04% 135.53%
Gross Profit Margin 2.06% -72.47% 69.38%
Selling, General & Admin $6.230M $7.259M $5.050M
YoY Change 6.64% 32.32% -2.7%
% of Gross Profit 47923.08% 282.12%
Research & Development $3.312M $3.870M $1.900M
YoY Change 117.61% 175.44% 36.69%
% of Gross Profit 25476.92% 106.15%
Depreciation & Amortization $429.0K $431.0K $430.0K
YoY Change -2.5% 0.23% -2.27%
% of Gross Profit 3300.0% 24.02%
Operating Expenses $9.542M $11.13M $6.960M
YoY Change 29.58% 61.5% 5.78%
Operating Profit -$9.529M -$11.58M -$5.170M
YoY Change 77.28% 37.03% -11.17%
Interest Expense $2.078M $2.009M -$1.740M
YoY Change 257.66% 319.42% 923.53%
% of Operating Profit
Other Income/Expense, Net -$20.00K -$17.00K $0.00
YoY Change -110.31% -121.79% -100.0%
Pretax Income -$12.19M -$14.08M -$8.770M
YoY Change 55.0% 52.42% 47.15%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.19M -$14.08M -$8.770M
YoY Change 55.0% 52.42% 47.15%
Net Earnings / Revenue -1935.24% -3657.4% -339.92%
Basic Earnings Per Share -$0.27 -$0.31
Diluted Earnings Per Share -$0.27 -$0.31 -$116.7K
COMMON SHARES
Basic Shares Outstanding 45.84M 45.04M
Diluted Shares Outstanding 45.84M 45.04M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.38M $21.99M $8.090M
YoY Change 816.67% 628.21% 131.14%
Cash & Equivalents $12.38M $21.99M $8.090M
Short-Term Investments
Other Short-Term Assets $4.912M $14.73M $2.360M
YoY Change 96.48% 545.88% 7.27%
Inventory $4.513M $3.402M $2.782M
Prepaid Expenses
Receivables $2.111M $4.134M $2.098M
Other Receivables $94.00K $40.00K $28.00K
Total Short-Term Assets $24.01M $44.29M $17.79M
YoY Change 123.93% 281.52% 86.89%
LONG-TERM ASSETS
Property, Plant & Equipment $658.0K $666.0K $677.0K
YoY Change -4.64% -4.86% -4.65%
Goodwill
YoY Change
Intangibles $23.07M $23.49M $24.34M
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.48M $0.00 $40.00K
YoY Change 14868.57% -100.0% -73.33%
Total Long-Term Assets $35.25M $25.25M $25.05M
YoY Change 38.18% -2.79% -6.84%
TOTAL ASSETS
Total Short-Term Assets $24.01M $44.29M $17.79M
Total Long-Term Assets $35.25M $25.25M $25.05M
Total Assets $59.26M $69.54M $42.84M
YoY Change 63.55% 85.04% 17.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.786M $4.918M $4.759M
YoY Change -30.66% -6.15% -11.05%
Accrued Expenses $6.084M $6.383M $4.493M
YoY Change -12.84% 28.43% 37.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.781M $1.145M $3.790M
YoY Change -73.73% -87.22% -44.1%
Total Short-Term Liabilities $11.95M $12.65M $13.22M
YoY Change -53.62% -48.9% -14.1%
LONG-TERM LIABILITIES
Long-Term Debt $24.93M $24.20M $12.42M
YoY Change 837.07% 5948.75% 2660.0%
Other Long-Term Liabilities $826.0K $907.0K
YoY Change
Total Long-Term Liabilities $25.75M $25.10M $12.42M
YoY Change 868.12% 6175.5% 2660.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.95M $12.65M $13.22M
Total Long-Term Liabilities $25.75M $25.10M $12.42M
Total Liabilities $37.70M $37.75M $25.64M
YoY Change 32.62% 50.06% 61.88%
SHAREHOLDERS EQUITY
Retained Earnings -$205.2M -$193.0M -$166.9M
YoY Change
Common Stock $226.7M $224.8M $184.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.55M $31.79M $17.20M
YoY Change
Total Liabilities & Shareholders Equity $59.26M $69.54M $42.84M
YoY Change 63.55% 85.04% 17.67%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q4
OPERATING ACTIVITIES
Net Income -$12.19M -$14.08M -$8.770M
YoY Change 55.0% 52.42% 47.15%
Depreciation, Depletion And Amortization $429.0K $431.0K $430.0K
YoY Change -2.5% 0.23% -2.27%
Cash From Operating Activities -$9.432M -$9.905M -$4.060M
YoY Change 223.01% 147.62% 29.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$6.000K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$10.48M
YoY Change
Cash From Investing Activities -$10.48M -$6.000K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 373.0K 9.573M 10.80M
YoY Change -70.16% 76.62% 118.18%
NET CHANGE
Cash From Operating Activities -9.432M -9.905M -4.060M
Cash From Investing Activities -10.48M -6.000K 0.000
Cash From Financing Activities 373.0K 9.573M 10.80M
Net Change In Cash -19.54M -338.0K 6.740M
YoY Change 1069.88% -123.8% 272.38%
FREE CASH FLOW
Cash From Operating Activities -$9.432M -$9.905M -$4.060M
Capital Expenditures $0.00 -$6.000K $0.00
Free Cash Flow -$9.432M -$9.899M -$4.060M
YoY Change 223.01% 147.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45840262
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13406088
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44167885
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8822463
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45840262
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13406088
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44167885
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8822463
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
dei Entity Central Index Key
EntityCentralIndexKey
0001585608
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Security Exchange Name
SecurityExchangeName
NASDAQ
jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2020Q3 jagx Collaboration Revenue Net
CollaborationRevenueNet
0
jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2021Q3 jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
33.33
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
33.33
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36714
dei Entity Registrant Name
EntityRegistrantName
JAGUAR HEALTH, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2956775
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Pine Street, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94104
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
371-8300
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
dei Trading Symbol
TradingSymbol
JAGX
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12375000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8090000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2111000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2098000
CY2020Q4 us-gaap Accounts Receivable From Securitization
AccountsReceivableFromSecuritization
2434000
CY2021Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
94000
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
28000
CY2021Q3 us-gaap Inventory Net
InventoryNet
4513000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2782000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4912000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2360000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
24005000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
17792000
CY2021Q3 us-gaap Advances To Affiliate
AdvancesToAffiliate
10478000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
658000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
677000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1042000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23072000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24337000
CY2020Q4 us-gaap Other Assets
OtherAssets
37000
CY2021Q3 us-gaap Assets
Assets
59255000
CY2020Q4 us-gaap Assets
Assets
42843000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3786000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4759000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6084000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4493000
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
3000
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
179000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297000
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
1781000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3789000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11951000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13220000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
826000
CY2021Q3 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
7500000
CY2020Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
0
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
24926000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4509000
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
617000
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
784000
us-gaap Cost Of Revenue
CostOfRevenue
1864000
us-gaap Cost Of Revenue
CostOfRevenue
2491000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3312000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1522000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9597000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
12421000
CY2021Q3 us-gaap Liabilities
Liabilities
37703000
CY2020Q4 us-gaap Liabilities
Liabilities
25641000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
226728000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
184097000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-205181000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166899000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
21552000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17202000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59255000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42843000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2261000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1529000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6596000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4728000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3969000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4313000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12450000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11218000
jagx Warrants Inducement Expense
WarrantsInducementExpense
1462000
jagx Warrants Inducement Expense
WarrantsInducementExpense
3696000
jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
jagx Convertible Preferred Stock Inducement Expense
ConvertiblePreferredStockInducementExpense
1647000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
10159000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
8148000
us-gaap Costs And Expenses
CostsAndExpenses
32141000
us-gaap Costs And Expenses
CostsAndExpenses
28289000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9529000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5375000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29886000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21480000
CY2021Q3 us-gaap Interest Expense
InterestExpense
2078000
CY2020Q3 us-gaap Interest Expense
InterestExpense
581000
us-gaap Interest Expense
InterestExpense
5988000
us-gaap Interest Expense
InterestExpense
1259000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-753000
CY2021Q3 jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
565000
CY2020Q3 jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
2104000
jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
1639000
jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
2491000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
194000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
190000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12192000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8822463
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
31785000
CY2021Q3 jagx Stock Issued During Period Redemption Of Convertible Preferred Stock Under Exchange Transaction
StockIssuedDuringPeriodRedemptionOfConvertiblePreferredStockUnderExchangeTransaction
776000
CY2020Q3 jagx Stock Issued In Exchange Of Cvp Exchange Notes
StockIssuedInExchangeOfCvpExchangeNotes
1498000
CY2021Q3 jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
16000
CY2021Q3 jagx Stock Issued In Exchange Of Cvp Exchange Notes
StockIssuedInExchangeOfCvpExchangeNotes
2000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7866000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38282000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25040000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12192000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7866000
us-gaap Net Income Loss
NetIncomeLoss
-38282000
us-gaap Net Income Loss
NetIncomeLoss
-25040000
CY2021Q3 jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-12192000
CY2020Q3 jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-8271000
jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-38282000
jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-27284000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.09
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45840262
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13406088
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44167885
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1165000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-12192000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
21552000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1544000
CY2020Q3 jagx Stock Issued During Period Redemption Of Convertible Preferred Stock Under Exchange Transaction
StockIssuedDuringPeriodRedemptionOfConvertiblePreferredStockUnderExchangeTransaction
4867000
CY2020Q3 jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
879000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
349000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
675000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-7866000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
7806000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17202000
jagx Stock Issued During Period Value Extinguishment Of Convertible Securities
StockIssuedDuringPeriodValueExtinguishmentOfConvertibleSecurities
2516000
jagx Stock Issued During Period In Exchange Of Notes Payable And Accrued Interest
StockIssuedDuringPeriodInExchangeOfNotesPayableAndAccruedInterest
2982000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
16000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2832000
us-gaap Profit Loss
ProfitLoss
-38282000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
21552000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10673000
jagx Stock Issued During Period Redemption Of Convertible Preferred Stock Under Exchange Transaction
StockIssuedDuringPeriodRedemptionOfConvertiblePreferredStockUnderExchangeTransaction
4867000
jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
916000
jagx Stock Issued In Exchange Of Cvp Exchange Notes
StockIssuedInExchangeOfCvpExchangeNotes
1498000
us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
1332000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2184000
us-gaap Profit Loss
ProfitLoss
-25040000
jagx Expense On Modification Of Warrants
ExpenseOnModificationOfWarrants
86000
jagx Common Stock And Warrants Issued
CommonStockAndWarrantsIssued
76000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
7806000
jagx Non Cash Consideration Paid Up On Acquisition Of Business Issuance Of Equity
NonCashConsiderationPaidUpOnAcquisitionOfBusinessIssuanceOfEquity
33000
us-gaap Profit Loss
ProfitLoss
-38282000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-37000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-88000
jagx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
36000
jagx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-337000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-986000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
90000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1369000
jagx Loss On Recourse Obligation On Secured Borrowing
LossOnRecourseObligationOnSecuredBorrowing
-30000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2421000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2963000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
66000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1731000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1061000
us-gaap Profit Loss
ProfitLoss
-25040000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3633000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
693000
us-gaap Share Based Compensation
ShareBasedCompensation
2832000
us-gaap Share Based Compensation
ShareBasedCompensation
2184000
jagx Warrants Issued As Inducement To Exercise Equity Classified Warrants
WarrantsIssuedAsInducementToExerciseEquityClassifiedWarrants
1462000
jagx Warrants Issued As Inducement To Exercise Equity Classified Warrants
WarrantsIssuedAsInducementToExerciseEquityClassifiedWarrants
3696000
jagx Fair Value Adjustment Of Financial Instruments And Hybrid Instrument Designated At Fair Value Of Option
FairValueAdjustmentOfFinancialInstrumentsAndHybridInstrumentDesignatedAtFairValueOfOption
-1639000
jagx Fair Value Adjustment Of Financial Instruments And Hybrid Instrument Designated At Fair Value Of Option
FairValueAdjustmentOfFinancialInstrumentsAndHybridInstrumentDesignatedAtFairValueOfOption
-2491000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1290000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1296000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-753000
jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
jagx Derecognition Of Debt Discount
DerecognitionOfDebtDiscount
49000
jagx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
45000
jagx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
553000
jagx Common Stock Issued In Exchange Of Services Rendered
CommonStockIssuedInExchangeOfServicesRendered
16000
jagx Common Stock Issued In Exchange Of Services Rendered
CommonStockIssuedInExchangeOfServicesRendered
916000
jagx Inducement Expense
InducementExpense
1647000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2002000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4482000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26047000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11217000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
10478000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10484000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10975000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
350000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
486000
jagx Repayment Of Receivables Secured Borrowing
RepaymentOfReceivablesSecuredBorrowing
1822000
us-gaap Premiums Receivable Proceeds From Sale Of Receivables
PremiumsReceivableProceedsFromSaleOfReceivables
776000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1349000
jagx Repayment Of Insurance Premium Fee Classified As Financing Activity
RepaymentOfInsurancePremiumFeeClassifiedAsFinancingActivity
588000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
100000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12375000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1349000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-205200000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3140000
jagx Payment Of Equity Line Of Credit Warrant Offering Cost
PaymentOfEquityLineOfCreditWarrantOfferingCost
35000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
640000
jagx Proceeds From Sale Of Finance Receivable
ProceedsFromSaleOfFinanceReceivable
4542000
jagx Payments Of Warrant Issuance Costs
PaymentsOfWarrantIssuanceCosts
-185000
jagx Payments Of Deferred Offering Cost
PaymentsOfDeferredOfferingCost
-7000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40816000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8690000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4285000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2534000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8090000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3883000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12375000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1349000
us-gaap Interest Paid Net
InterestPaidNet
21000
us-gaap Interest Paid Net
InterestPaidNet
343000
jagx Shares Issued In Extinguishment Of Exchange Note
SharesIssuedInExtinguishmentOfExchangeNote
2982000
jagx Umbrella Insurance Financing
UmbrellaInsuranceFinancing
1183000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1087000
jagx Reversal Of Deferred Offering Costs
ReversalOfDeferredOfferingCosts
13000
jagx Reversal Of Deferred Offering Costs
ReversalOfDeferredOfferingCosts
-166000
jagx Business Combination Consideration Common Stock Issued In Relation To Redemption Of Notes Payable And Related Interest
BusinessCombinationConsiderationCommonStockIssuedInRelationToRedemptionOfNotesPayableAndRelatedInterest
1498000
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
11377000
jagx Non Cash Stock Dividend Issued
NonCashStockDividendIssued
56000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12375000
us-gaap Profit Loss
ProfitLoss
-25040000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its unaudited condensed consolidated financial statements and the accompanying notes. The accounting policies that reflect the Company’s more significant estimates and judgments and that the Company believes are the most critical to aid in fully understanding and evaluating its reported financial results are the valuation of stock options, valuation of hybrid instruments designated at fair value option (“FVO”), valuation of warrant liabilities, acquired in-process research and development (“IPR&amp;D”), and useful lives assigned to long-lived assets; valuation adjustments for excess and obsolete inventory; allowance for doubtful accounts; deferred taxes and valuation allowances on deferred tax assets; evaluation and measurement of contingencies; and recognition of revenue, including estimates for product returns. Those estimates could change, and as a result, actual results could differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, the World Health Organization declared the COVID-19 outbreak to be a pandemic. During the period ended September 30, 2021, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it.</p>
jagx Accounts Receivable Outstanding Period For Write Off
AccountsReceivableOutstandingPeriodForWriteOff
P2Y
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2021Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2020Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Revenue Practical Expedient Initial Application And Transition Nondisclosure Of Transaction Price Allocation To Remaining Performance Obligation
RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation
true
jagx Number Of Contracts
NumberOfContracts
2
CY2021Q3 jagx Number Of Specialty Pharmacies
NumberOfSpecialtyPharmacies
2
jagx Number Of Portfolio Of Contract
NumberOfPortfolioOfContract
1
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reclassification of Prior Period Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>Certain prior period amounts of cash flows from financing activities in the unaudited condensed consolidated statements of cash flows have been reclassified within the same category of cash flow activity to be consistent with the current period presentation. There were no reclassifications to other categories of cash flow activity and that the reclassification did not impact the profit or loss during the prior period.</p>
jagx Modifications To Liability Classified Instruments
ModificationsToLiabilityClassifiedInstruments
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modifications to Liability-classified Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accounting for debt modifications and exchange transactions, it is the Company’s policy to first determine whether it qualifies as a troubled debt restructuring (“TDR”) pursuant to the guidance provided in ASC 470-60. A debt modification or exchange transaction that is not within the scope of the ASC 470-60 is accounted for under ASC 470-50 to determine if the transaction is a mere modification or an extinguishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company amended the terms of its October 2020 Purchase Agreement and Exchange Note 2 in the nine months ended September 30, 2021 (see Note 7). The Company did not modify any liability-classified instrument in the three months ended September 30, 2021. The Company also amended the terms of its Exchange Note 1, Exchange Note 2, and March 2020 Purchase Agreement in the three months and nine months ended September 30, 2020 (see Note 7).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p>
jagx Modifications To Equity Classified Instruments
ModificationsToEquityClassifiedInstruments
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Modifications to Equity-classified Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accounting for modifications of equity-classified warrants, it is the Company’s policy to determine the impact by analogy to the share-based compensation guidance of ASC 718, <i style="font-style:italic;">Compensation - Stock Compensation </i>(“ASC 718”). The model for a modified share-based payment award that is classified as equity and remains classified in equity after the modification is addressed in ASC 718-20-35-3. Pursuant to that guidance, the incremental fair value from the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">modification is recognized as an expense in the statements of operations to the extent the modified instrument has a higher fair value; however, in certain circumstances, such as when an entire class of warrants is modified, the measured increase in fair value may be more appropriately recorded as a deemed dividend, depending upon the nature of the warrant modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company modified certain equity-classified warrants in the nine months ended September 30, 2020 (see Note 8). The Company did not modify any equity-classified warrants in the three months ended September 30, 2020 and in the three and nine months ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accounting for amendments to preferred stock, it is the Company’s policy to measure the impact by analogy to ASC 470-50 in determining if such an amendment is an extinguishment or a modification. If the amendment results in an extinguishment, the Company follows the SEC staff guidance in ASC 260-10-S99-2 and ASC 470-20. If the amendment results in a modification, the Company follows the model in either ASC 718 or ASC 470-50, depending on the nature of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company modified the terms of its Series B convertible preferred stock in the nine months ended <br/>September 30, 2020 (see Note 9). The Company did not modify any preferred stock in the three months ended September 30, 2020 and in the three and nine months ended September 30, 2021.</p>
CY2021Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
3000
CY2021Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
7505000
CY2020Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
179000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
179000
CY2021Q3 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
7502000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6000000
CY2021Q3 us-gaap Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
1502000
CY2021Q3 jagx Payment Of Loan To Spc
PaymentOfLoanToSPC
10500000
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1206000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1321000
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2202000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1026000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1105000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
435000
CY2021Q3 us-gaap Inventory Net
InventoryNet
4513000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2782000
CY2017Q3 jagx Percentage Of Amount Received To Be Paid To Glenmark
PercentageOfAmountReceivedToBePaidToGlenmark
0.25
CY2017Q3 jagx Maximum Amount To Be Received By Glenmark
MaximumAmountToBeReceivedByGlenmark
7000000.0
CY2017Q3 jagx Payments Made To Date To Glenmark
PaymentsMadeToDateToGlenmark
0
CY2018Q3 jagx Period To Amend Complaint From Date Of Dismissal
PeriodToAmendComplaintFromDateOfDismissal
P20D
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1021165
CY2019Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
166
CY2020Q4 jagx Carrying Amount In Excess Of Fair Value Amount New Instruments
CarryingAmountInExcessOfFairValueAmountNewInstruments
2500000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24337000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
422000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
948000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
942000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
290000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
265000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
658000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
677000
CY2021Q3 jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
8000
jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
25000
CY2020Q3 jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
11000
jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
31000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23072000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
422000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
422000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1687000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1687000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1687000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1687000
CY2021Q3 jagx Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
11102000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18272000
CY2019Q3 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
2600000
CY2021Q2 us-gaap Unusual Or Infrequent Item Insurance Proceeds
UnusualOrInfrequentItemInsuranceProceeds
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1485518
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1162238
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
753000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
198866
CY2018Q3 jagx Letter Of Credit Received As Collateral
LetterOfCreditReceivedAsCollateral
475000
CY2018Q3 jagx Letter Of Credit Received As Collateral
LetterOfCreditReceivedAsCollateral
475000
CY2018Q3 jagx Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
9580
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1042000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
826000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1123000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y11M1D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.2110
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
126000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
510000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
526000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
357000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1519000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
396000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1123000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
826000
CY2020Q3 jagx Collaboration Agreement Term
CollaborationAgreementTerm
P2Y6M
CY2020Q3 jagx Collaboration Agreement Extension Term
CollaborationAgreementExtensionTerm
P2Y
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2401818
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6473964
jagx Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
168750
CY2020 jagx Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
7349426
jagx Class Of Warrant Or Right Exercises
ClassOfWarrantOrRightExercises
-2007117
CY2020 jagx Class Of Warrant Or Right Exercises
ClassOfWarrantOrRightExercises
-11421464
CY2020 jagx Class Of Warrant Or Right Subject To Expire
ClassOfWarrantOrRightSubjectToExpire
108
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
563451
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2401818
CY2019Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5100000
CY2019Q1 jagx Number Of Promissory Notes Issued
NumberOfPromissoryNotesIssued
21
CY2019Q2 jagx Number Of Promissory Notes Issued
NumberOfPromissoryNotesIssued
21
CY2019Q3 jagx Class Of Warrant Or Right Number Of Securities Exercisable
ClassOfWarrantOrRightNumberOfSecuritiesExercisable
927083
CY2019Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
4300000
CY2020Q1 jagx Class Of Warrant Or Right Number Of Securities Exercisable
ClassOfWarrantOrRightNumberOfSecuritiesExercisable
69340
CY2020Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
653000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-12192000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-7866000
jagx Schedule Of Common Stock Reserved For Future Issuance
ScheduleOfCommonStockReservedForFutureIssuance
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:middle;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,301,513</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,485,518</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inducement options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 156,204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,293</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options available for grant under stock option plans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,162,238</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 198,866</p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock unit awards issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,871</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued and outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 563,451</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,401,818</p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,185,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,126,366</p></td></tr></table>
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2301513
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1871
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1871
CY2021Q3 jagx Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued And Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuedAndOutstandingNumber
563451
CY2020Q4 jagx Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued And Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuedAndOutstandingNumber
2401818
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4185277
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4126366
jagx Common Stock Voting Rights Number
CommonStockVotingRightsNumber
1
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
10 years
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.68
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.60
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.34
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.71
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
495023
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
355013
jagx Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValueAmount
4.55
jagx Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValueAmount
6.34
us-gaap Profit Loss
ProfitLoss
-38282000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1165000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
675000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2832000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2184000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2021Q3 jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-12192000
CY2020Q3 jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-8271000
jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-38282000
jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-27284000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45840262
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13406088
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44167885
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8822463
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.09
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3023039
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4428858
CY2021Q3 us-gaap Investments
Investments
29241000
CY2020Q4 us-gaap Investments
Investments
29241000
CY2021Q3 jagx Loans Receivable Asset
LoansReceivableAsset
71906000
CY2020Q4 jagx Loans Receivable Asset
LoansReceivableAsset
41877000
CY2021Q3 us-gaap Assets
Assets
59255000
CY2020Q4 us-gaap Assets
Assets
42843000

Files In Submission

Name View Source Status
0001558370-21-016117-index-headers.html Edgar Link pending
0001558370-21-016117-index.html Edgar Link pending
0001558370-21-016117.txt Edgar Link pending
0001558370-21-016117-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
jagx-20210930.xsd Edgar Link pending
jagx-20210930x10q.htm Edgar Link pending
jagx-20210930x10q_htm.xml Edgar Link completed
jagx-20210930xex31d1.htm Edgar Link pending
jagx-20210930xex31d2.htm Edgar Link pending
jagx-20210930xex32d1.htm Edgar Link pending
jagx-20210930xex32d2.htm Edgar Link pending
jagx-20210930_cal.xml Edgar Link unprocessable
jagx-20210930_def.xml Edgar Link unprocessable
jagx-20210930_lab.xml Edgar Link unprocessable
jagx-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending